Clinical Trials

122 enrolled

Anal Cancer Metastatic

NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT04274426 2026-05-13

MIROVA

136 enrolled

Gynecologic

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03819465 2026-05-12

MAGELLAN

175 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04658862 2026-05-08

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06211764 2026-05-08

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06608927 2026-05-08

PRISM-1

610 enrolled

Pancreatic Neoplasms

NCT04104672 2026-05-07

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT05171647 2026-05-07

SUNMO

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Active not recruiting

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04542824 2026-05-05

EPCORE™ NHL-3

LymphoidOther hematologic neoplasm

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02542293 2026-05-01

NEPTUNE

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT04241185 2026-05-01

MK-3475-992

520 enrolled

Urinary Bladder Neoplasms

NCT02486718 2026-04-30

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT04384484 2026-04-28

LOTIS 5

440 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

GastrointestinalGenitourinaryThoracic

102 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT06625320 2026-04-27

RASolute 302

500 enrolled

Pancreatic Neoplasms

NCT03967977 2026-04-23

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

200 enrolled

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05771480 2026-04-21

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

418 enrolled

Triple Negative Breast Neoplasms

NCT06118333 2026-04-17

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

386 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

383 enrolled

HR+HER2- Breast Cancer

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

223 enrolled

Camurati-Engelmann Syndrome

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT03816163 2026-03-12

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

393 enrolled

Pancreatic Neoplasms

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Phase 2/3 Active not recruiting

Non Small Cell Lung Carcinoma NSCLC

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors